Eric Siemers, MD

Eric Siemers, MD
Medical Director, Alzheimer’s Disease
Eli Lilly

Eric Siemers, M.D. is Medical Director of the Alzheimer’s Disease Team at Eli Lilly and a Clinical Associate Professor of Neurology at the Indiana University School of Medicine. He earned his MD with highest distinction from the Indiana University School of Medicine in Indianapolis in 1982. After an internship in the Department of Internal Medicine at the Indiana University School of Medicine, he completed his residency in the Department of Neurology in 1986. Prior to joining Lilly, his previous research included investigations of Huntington’s disease and Parkinson’s disease.

Dr. Siemers currently directs late stage clinical research efforts at Lilly concerning investigational treatments for Alzheimer’s disease, and is more broadly involved with other neurological indications such as Parkinson’s disease. Major research interests include the use of biomarkers in investigational drug research and the development of trial designs that broadly characterize the effects of investigational drugs on chronic diseases.

Dr. Siemers is a member of the Alzheimer’s Association Research Roundtable and is a member of the Steering Committee for the NIA-funded Alzheimer’s Disease Neuroimaging Initiative, where he also served as the chair of the Industry Scientific Advisory Board in 2007. He is a member of the Biomarker Consortium established by the Foundation for the NIH, and is a past member of the Board of Directors of the American Society of Experimental Neurotherapeutics. Dr. Siemers serves on steering committees for NIH-funded studies regarding the genetics of Parkinson’s disease and clinical progression in presymptomatic subjects with Huntington’s disease.